VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MNPRMonopar Therapeutics Inc.
$70.75$474M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MNPR
  4. Financial Ratios

Monopar Therapeutics Inc. (MNPR) Financial Ratios

Latest Ratios: P/E Ratio -29.4x · EV/EBITDA N/A · ROE -14.2%. (2015–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MNPR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$474M$484M$253M$25M$151M$200M$335M$879M———
Enterprise Value$412M$422M$207M$17M$143M$180M$319M$866M———
P/E Ratio →-29.40——————————
P/S Ratio———————————
P/B Ratio3.803.514.594.4114.9410.5721.3769.59———
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

MNPR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue———————————
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

MNPR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin———————————
Operating Margin———————————
Net Profit Margin———————————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-14.2%-14.2%-51.4%-107.2%-72.4%-52.6%-44.5%-43.2%-39.0%-265.9%-42.5%
ROA-13.6%-13.6%-46.1%-81.7%-62.3%-48.7%-41.7%-40.9%-37.4%-258.1%-41.4%
ROIC-29.4%-29.4%-321.4%-5671.9%-2878.6%———-769.7%-1784.1%-118.7%
ROCE-17.3%-17.3%-53.3%-112.6%-72.6%-52.7%-46.0%-44.2%-41.2%-266.7%-42.7%

MNPR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.000.00——0.00——————
Debt / EBITDA———————————
Net Debt / Equity—-0.45-0.83-1.30-0.81-1.07-1.07-1.05-1.00-0.93-0.73
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage————————-32.27-343.07-163.83

Net cash position: cash ($62M) exceeds total debt ($154920)

MNPR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio51.3551.3511.474.174.2112.9814.2818.2718.3229.2832.48
Quick Ratio51.3551.3511.474.174.2112.9814.2818.2718.3229.2832.48
Cash Ratio51.3351.3311.464.134.1912.8514.2218.2517.2528.8032.13
Asset Turnover———————————
Inventory Turnover———————————
Days Sales Outstanding———————————

MNPR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield7.4%7.2%0.0%0.0%0.0%0.0%0.0%0.0%———
Total Shareholder Yield7.4%7.2%0.0%0.0%0.0%0.0%0.0%0.0%———
Shares Outstanding—$7M$11M$15M$13M$12M$11M$11M$10M$10M$10M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Finite cash runway without revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Negative Earnings Leave P/E Uninformative

With trailing P/E at -29.92 and a P/B of 3.87 against a pre-revenue cost base, reported figures suggest the market is pricing MNPR on its clinical pipeline rather than on earnings or book value.

A negative P/E is not meaningful as a valuation anchor, so the 3.87 P/B becomes the more informative multiple, though book value here is largely cash that is being consumed at roughly $6M per quarter. Compared with its own history and the sampled peers, the premium to book appears to reflect option value on MNPR-101 and Validive rather than any earnings base. Investors should treat the multiple as contingent on clinical readouts and monitor whether book value erodes faster than the market's implied pipeline value.

Losses Persist With No Revenue Offset

Gross, operating, and net margins are unavailable because MNPR reports zero revenue, while ROE of -4.8% and ROA of -4.7% in 2026Q3 show continuing losses against a small equity base.

The absence of revenue means margin analysis cannot distinguish earning power from cost structure, so the return metrics are the only usable profitability signal. ROE has improved from roughly -36% in 2024Q4 to near -4% in recent quarters, but this reflects a larger equity base rather than operating improvement, as net losses remain around $6M per quarter. The trajectory suggests the loss rate is stable, and sustainability depends on whether funding persists long enough for pipeline catalysts.

ROIC Turning Less Negative Recently

ROIC moved from -22.9% in 2025Q3 to -4.9% in 2026Q1 and -7.3% in 2026Q3, indicating that invested capital is being consumed at a slower rate than in 2025, though returns remain deeply negative.

The improvement in ROIC appears driven more by a larger invested capital base than by any reduction in losses, which is consistent with the balance sheet expansion seen in 2025. Peer ROIC values vary widely, with CLDX at -35.2% and NKTR at -57.2%, so MNPR's recent figures sit toward the less-negative end of the clinical-stage group. Based on these reported figures, the metric is best read as evidence of capital preservation rather than value creation until revenue exists.

Current Ratio Overstates Cushion

A current ratio of 43.55 in 2026Q3 is driven almost entirely by cash, which has fallen from $61.8M at year-end 2025 to $52.6M, against quarterly operating burn of roughly $6M.

The headline liquidity ratio is extreme because MNPR holds almost no operating liabilities, so it reflects cash concentration rather than operating strength. Quick and current ratios are identical given the lack of inventory, meaning liquidity analysis reduces to cash divided by burn. At the current burn rate the reported cash position implies a finite runway of several years at most, which appears to make future equity financing a probable requirement, though this is an inference from reported figures rather than a disclosed plan.

Current Ratio Misleads on Runway

The most commonly misapplied ratio for a pre-revenue biotech is the current ratio, which at 43.55 suggests strength while obscuring that cash burn, not working capital, determines survival.

Analysts often read a high current ratio as evidence of financial health, but for a company with no revenue and no inventory it simply reflects that nearly all assets are cash awaiting consumption by trials. A more appropriate measure is cash runway, calculated as cash divided by the trailing quarterly operating burn, alongside net cash per share. Investors should monitor the runway figure and any shift toward dilutive financing, since the reported liquidity ratio alone does not indicate how long the cash lasts.

Download Financial Ratios Data

Includes 30+ ratios · 11 years · Updated daily

Consensus & Technical Research Suite
Open MNPR Terminal

MNPR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MNPR — Frequently Asked Questions

Quick answers to the most common questions about buying MNPR stock.

What is Monopar Therapeutics Inc.'s P/E ratio?

Monopar Therapeutics Inc.'s current P/E ratio is -29.4x. This places it at the 50th percentile of its historical range.

What is Monopar Therapeutics Inc.'s ROE?

Monopar Therapeutics Inc.'s return on equity (ROE) is -14.2%. The historical average is -68.9%.

Is MNPR stock overvalued?

Based on historical data, Monopar Therapeutics Inc. is trading at a P/E of -29.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.